REVENIO

Revenio Group Corporation: Half-Year Report

January 1 – June 30, 2026

Revenio Group Corporation: Half-Year Report January 1 – June 30, 2026

Q2/2026: Business developed steadily – building the new Revenio is progressing according to plan

The figures in parentheses refer to the corresponding period in the previous year unless otherwise stated.

Revenio acquired the entire share capital of the Visionix International Group ("Visionix") from its parent company, LT International SAS.

The debt-free, cash-free value of the transaction (enterprise value) was EUR 290 million. The consideration paid to the sellers was EUR 250 million, of which EUR 55.7 million was paid in the form of 2,485,797 new shares in Revenio.

Visionix has been consolidated into Revenio as of June 2026. A separate acquisition cost calculation related to the acquisition is presented on page 31 of this half-year report.

April–June 2026

- Net sales totaled EUR 39.3 (26.5) million, up by 48.1%. Visionix has been included in the Group figures since the beginning of June.
- The currency-adjusted increase of net sales in April-June was 50.7%
- Operating profit was EUR 2.4 (6.1) million, or 6.1% of net sales, down by 60.9%. Operating profit was affected by non-recurring expenses arising from the acquisition, totalling approximately EUR 3.4 million.
- The adjusted operating profit was EUR 5.8 (6.6) million, or 14.6% of net sales, down by 12.3%
- EBITDA was EUR 4.3 (7.2) million, or 10.9% of net sales, down by 40.9%
- Cash flow from operating activities totaled EUR -2.4 (6.7) million
- Earnings per share came to EUR 0.020 (0.116)
- Visionix integration has progressed in a planned manner following the completion of the transaction. The integration work has focused on ensuring business continuity and securing customer relationships, as well as building a common organisation, operating models and culture.
- Revenio will host a Capital Markets Day on 15 September 2026, during which Revenio's updated strategy will be presented

January–June 2026

- Net sales totaled EUR 66.6 (52.6) million, up by 26.6%
- The currency-adjusted growth of net sales was 28.8%
- Operating profit was EUR 4.8 (12.7) million, or 7.2% of net sales, down by 62.4%. Operating profit was affected by non-recurring expenses arising from the acquisition, totalling approximately EUR 6.9 million.
- The adjusted operating profit was EUR 11.7 (13.2) million, or 17.5% of net sales, down by 11.6%
- EBITDA was EUR 7.8 (15.0) million, or 11.7% of net sales, down by 48.1%
- Cash flow from operating activities totaled EUR -5.8 (11.4) million
- Earnings per share came to EUR 0.112 (0.273)
- The Annual General Meeting was held on May 12, 2026. The AGM decided no dividend for the financial year 2025 will be paid.

NET SALES
Q2/2026

39.3 (26.5) M€

+48.1%

ADJUSTED OPERATING PROFIT Q2/2026

5.8 (6.6) M€

-12.3%

EBITDA
Q2/2026

4.3 (7.2) M€

-40.9%

EPS
Q2/2026

0.020 (0.116) €

CURRENCY-ADJUSTED NET SALES Q2/2026

+50.7%

Key consolidated figures

MEUR	4-6/2026	4-6/2025	Change-%	1-6/2026	1-6/2025	Change-%
Net sales	39.3	26.5	48.1	66.6	52.6	26.6
Gross margin	25.4	19.3	31.8	44.1	38.2	15.4
Gross margin -%	64.7	72.6	-11.0	66.2	72.6	-8.8
EBITDA	4.3	7.2	-40.9	7.8	15.0	-48.1
EBITDA-%	10.9	27.3	-60.1	11.7	28.4	-59.0
EBITA	3.3	6.5	-49.3	6.1	13.6	-54.9
EBITA-%	8.4	24.6	-65.7	9.2	25.8	-64.4
Adjusted EBITA	6.7	7.0	-4.5	13.0	14.0	-7.5
Adjusted EBITA -%	17.0	26.4	-35.5	19.5	26.7	-26.9
Operating profit, EBIT	2.4	6.1	-60.9	4.8	12.7	-62.4
Operating profit-%, EBIT	6.1	23.0	-73.6	7.2	24.2	-70.3
Adjusted Operating profit, EBIT	5.8	6.6	-12.3	11.7	13.2	-11.6
Adjusted Operating profit -%, EBIT	14.6	24.7	-40.8	17.5	25.1	-30.2
Return on investment -%, ROI	1.2	4.3	-72.1	2.5	9.5	-73.7
Return on equity-%, ROE	0.5	2.9	17.2	2.3	6.9	-66.7
Earnings per share	0.020	0.116		0.112	0.273	
MEUR	**30.6.2026**	**30.6.2025**	**Change, %-point**			
Equity ratio-%	31.2	77.2	-46.0			
Gearing-%	159.2	-1.3	160.5			
Net debt / Adjusted EBITDA *	5.3	-0.04				

* Adjusted EBITDA in column 30.6.2026 is based on 2025 pro forma numbers and in column 30.6.2025 for historical rolling 12-month values.

Net sales, M€



Geographic distribution of net sales H1/2026, %



Adjusted operating profit, EBIT, M€



Adjusted EBITA, M€



Cash flow from operations, M€



Financial guidance for 2026

Revenio's new financial guidance:

Revenio Group's exchange rate-adjusted net sales are estimated to be between EUR 190 million and EUR 205 million and EBITA, excluding non-recurring items is estimated to remain at a satisfactory level.

The lower end of the range assumes continued softness in market demand and slower customer activity. The upper end assumes an improvement in market conditions combined with successful execution of commercial initiatives.

Revenio's previous financial guidance:

Due to the transaction announced on April 13, 2026, Revenio withdrew its previous financial guidance for the year 2026.

Comments from CEO Jouni Toijala

The second quarter of the year marked the beginning of a new phase for Revenio and the start of building the combined company. The completion of the Visionix acquisition at the end of May brought together two highly complementary companies and gave us an even stronger position in the global eye care market. As a result of the transaction, our product portfolio expanded significantly, our customer base became more diversified, and our global presence strengthened. At the same time, our total addressable market increased approximately 2.5-fold to more than EUR 2.5 billion, opening up new growth opportunities for us well into the future.

During the first months together, we have progressed as planned with the integration. We have focused in particular on ensuring business continuity and securing customer relationships, as well as on building a shared organization, operating models and culture. Our strengthened Board of Directors, Leadership Team and operational organization have already begun their work, and the early feedback received from employees has demonstrated strong commitment to building the new Revenio. Although the integration work is still ongoing, we have progressed well and partly ahead of the original schedule. The progress made so far reinforces our view of the strategic potential of the acquisition and the long-term value creation opportunities it offers.

As a combined company, we are able to serve optical retail, optometry and ophthalmology with a broader portfolio of diagnostics, imaging and workflow solutions across the eye care pathway. The feedback we have received from our customers on our stronger offering has been very positive. Revenio's and Visionix's highly complementary technologies, expertise and commercial capabilities, together with the limited overlap between the businesses, provide us with an excellent foundation for leveraging the growth opportunities created by the combination and for building long-term value. The experiences from the first months together have strengthened our view that together we can create more value than as separate companies. Leveraging our strengths and realizing the targeted synergies expected to uplift EBITDA by more than EUR 20 million will provide a strong foundation for the next phase of growth for the new Revenio. Approximately one quarter of these synergies has already been secured to date.

I am very pleased that we have maintained a strong focus on our customers and day-to-day business while advancing the most significant transaction in Revenio's history. Despite the significant changes brought about by a major acquisition, quarterly fluctuations and geopolitical uncertainties, our business remained stable. Our revenue for the second quarter was 39.3 (26.5) million euros, an increase of 48.1%. Visionix has been included in Revenio's consolidated figures since the beginning of June. During the quarter, net sales development in the old Revenio business was flat. Geopolitical and economic uncertainties had an impact on our market environment, especially in the Middle East and Asia.

After the review period, iCare entered into a strategic partnership with the U.S.-based EyeCheq and made a minority investment in the company to promote the accessibility of vision screening and the adoption of automated and AI-based screening solutions in the United States. In addition, the iCare DRSplus fundus camera is included in iHealthScreen's FDA-approved AI-based solution in the United States, enabling automated screening for diabetic retinopathy particularly in primary healthcare.

Profitability in the second quarter was at the level we expected. The combined profitability level was affected, as expected, by Visionix's lower profitability profile, and adjusted operating profit was 14.6% of net sales. Unadjusted profitability was affected by acquisition-related non-recurring expenses totaling approximately 3.4 million euros. As a result of the acquisition, our leverage has increased as expected, and the EUR 80 million rights issue to be carried out in the autumn will strengthen our financial position.

Our focus is now firmly on the next phases. We will continue the integration with determination and focus in particular on realizing the identified synergies as quickly as possible, developing the shared product portfolio and R&D roadmap, and harmonizing operating practices and processes. At our Capital Markets Day later in September, we will present our new strategy and provide more detail on our long-term targets and on how we intend to leverage the growth opportunities offered by our expanded product portfolio, global presence and commercial capabilities.

Our operating environment continues to involve geopolitical and economic uncertainty, and we are closely monitoring their impacts on our markets and customers. At the same time, we look ahead with confidence. We have a strong foundation, complementary expertise and technologies, and a shared determination to strengthen Revenio's position as a global leader in eye care. I want to thank all our employees for their excellent work and strong commitment during this significant phase of change, as well as our customers, partners and shareholders for their continued trust. We are only at the beginning of building the new Revenio, but the first months together have reinforced my confidence in what we can achieve together.

Revenio Group's strategy

The cornerstones of the strategy for 2024–2026 are:

- Improve the quality of clinical diagnostics with targeted product innovations
- Optimize clinical care pathways with connected and predictive solutions
- Enhance customer focus in operations & sales
- Continue to develop People & Culture as a foundational strength
- Continue sustainable and profitable growth

Revenio is updating its strategy following the acquisition of Visionix, which was completed in May 2026.
The updated strategy will be presented at the Capital Markets Day on September 15, 2026.

Revenio's key products

Revenio's growth strategy is driven by delivering the highest-quality products and solutions on the market under the iCare and Visionix brands. The diagnosis and treatment of eye diseases is shifting towards comprehensive patient-oriented and predictive solutions. Revenio is a pioneer in utilizing next-generation technology and artificial intelligence and improving the efficiency of care pathways. In 2025, the company invested 10.5% of net sales in research and development.

Intraocular pressure (IOP) measurement devices, i.e. tonometers

- Tonometers are innovative and easy-to-use devices for measuring intraocular pressure without anesthetic drops or air puff, making the measurement accurate and more comfortable for the patient. Tonometers are used for glaucoma screening and monitoring, and they are suitable for clinical, home and veterinary use.

Fundus imaging devices

- Fundus imaging devices provide accurate high-quality images of ocular structures, such as the retina and optic nerve end, and are used to diagnose and monitor fundus diseases, such as glaucoma, age-related macular degeneration, and diabetic retinopathy. The highly automated user-friendly devices utilize advanced technology to produce clear images without pupil dilation.

Fundus perimeters

- Fundus perimeters combine visual field examination, and exceptionally precise fundus imaging in one device for improved diagnostics accuracy. A single examination can determine both the structure and functionality of the fundus. These industry-leading devices are particularly used in the diagnosis and monitoring of glaucoma, as they allow the detection of visual field deficiencies and the evaluation of the effects of treatment.

Microperimeters

- A microperimeter combines retinal imaging and automatic visual field examination in one device, enabling simultaneous viewing of focused retinal sensitivity and monitoring of structural changes. Microperimeters are particularly used for the diagnosis and monitoring of macular degenerative diseases.

Screening solutions

- The iCare ILLUME-based screening solution combines TrueColor confocal fundus imaging with AI-powered analytics. This fully automated screening solution produces a reliable report on the patient's eye health by utilizing high-quality, detailed fundus images. Company's innovative fundus camera enables high-quality imaging without the need for uncomfortable eye drops for the patient, making the screening process fast and patient-friendly. iCare ILLUME uses artificial intelligence to help detect early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma. In addition, the ILLUME Connect product allows sharing referrals between healthcare professionals. The AI-powered iCare RETCAD software is offered as a part of iCare Screening Solution and also as an individual product.

Software solutions and telehealth

- The comprehensive software solutions support eye health monitoring and diagnostics by providing tools for patient data management, imaging data analysis, and long-term change tracking. They enable the integration and visualization of data collected from various devices, helping eye health professionals make accurate and up-to-date treatment decisions while streamlining care pathways.

OCT

- Optical coherence tomography (OCT) devices provide detailed cross-sectional and three-dimensional images of ocular structures using non-invasive imaging technology. OCT systems also provide OCT angiography (OCTA), enabling visualization of retinal and choroidal vasculature without the use of contrast agents. The high-resolution images help eye care professionals detect and monitor structural changes associated with eye diseases, such as glaucoma, age-related macular degeneration and diabetic retinal diseases. OCT/OCTA examinations support early diagnosis and monitoring of disease progression and treatment outcomes.

Multimodal devices

- Multimodal devices combine several diagnostic technologies within a single diagnostic platform to provide a comprehensive assessment of the eye. By combining measurements and imaging of different ocular structures, the devices help eye care professionals detect a wide range of eye conditions and support efficient clinical decision-making. Automated examination workflows also help make comprehensive eye examinations faster and more convenient for both patients and professionals.

Refraction systems

- Refraction systems provide accurate measurements that support the assessment of refractive error and the determination of appropriate vision correction. Automated measurement and digital refraction technologies help eye care professionals perform examinations efficiently and consistently, while supporting a smooth and comfortable examination experience for the patient. Connected solutions can also support remote refraction workflows, helping eye care providers extend access to professional expertise across different locations.

Edging & mounting

- Edging and mounting solutions enable ophthalmic lenses to be accurately measured, shaped and fitted into spectacle frames. Automated measurement, lens edging and mounting technologies support precise and consistent production of customized eyewear while improving the efficiency of the optical workflow. This helps ensure that patients receive correctly fitted, high-quality glasses that provide the intended vision correction and comfort.

Financial review

Net sales, profitability, and profit

April–June 2026

Revenio Group's net sales April 1–June 30, 2026 were EUR 39.3 (26.5) million. Net sales increased by 48.1%. The currency-adjusted increase of net sales was 50.7%.

Gross margin-% for the second quarter reduced to 64.7 (72.6)% driven by approximately 2 percentage points Visionix dilution impact and 5 percentage points reduction coming from underlying Revenio business driven, among other factors, by increased tariffs and increase in electronic components unit costs.

EBITDA was EUR 4.3 (7.2) million, or 10.9% of net sales. Profit before taxes was EUR 2.2 (4.4) million. The Group's operating profit in April–June was EUR 2.4 (6.1) million. The Group's adjusted operating profit in April–June was EUR 5.8 (6.6) million, impacted by reduced gross margin-% and an increase in overall fixed costs.

Earnings per share came to EUR 0.020 (0.116). Equity per share came to EUR 5.13 (3.91).

January–June 2026

Revenio Group's net sales January 1–June 30, 2026 was EUR 66.6 (52.6) million. Net sales increased by 26.6%. The currency-adjusted growth of net sales in January–June was 28.8%, or 2.2%-points stronger than the reported growth. EBITDA was EUR 7.8 (15.0) million, or 11.7% of net sales, down by 48.1%.

The Group's operating profit in January–June was EUR 4.8 (12.7) million, down by 62.4%. The adjusted operating profit was EUR 11.7 (13.2) million, or 17.5% of net sales.

Profit before taxes was EUR 5.5 (10.0) million.

Earnings per share came to EUR 0.112 (0.273). Equity per share came to EUR 5.13 (3.91).

Balance sheet, financial position and cash flow

The Group's balance sheet total totaled EUR 479.2 (135.2) million on June 30, 2026. The value of goodwill on the balance sheet totaled EUR 184.2 (62.8) million on June 30, 2026.

The Group's equity was EUR 149.5 (104.4) million. The Group's net debt at the end of the period totaled EUR 237.9 (-1.3) million, and net gearing was 159.2 (-1.3)%. The Group's equity ratio was 31.2 (77.2)%. The Group's liquid assets at the end of the review period on June 30, 2026 totaled EUR 17.8 (14.0) million. During H1/2026 cash flow from operations totaled EUR -5.8 (11.4) million and was negatively impacted by EUR 6.0 million integration payments and increased net working capital.

Revenio's liquidity position remained good during the reporting period. In connection with the acquisition of Visionix completed on 28 May 2026, the Group entered into a new financing arrangement comprising a EUR 130 million amortizing term loan facility with a maturity of four years and options to extend by up to 12 months, a EUR 80 million bridge-to-equity facility and a EUR 17 million vendor loan arrangement. In connection with the arrangement, Revenio repaid its existing bank loans with a nominal amount of EUR 3.8 million as of deal closing and Visionix's bank loans of EUR 58.3 million.The Group complies with all financing covenants and maintains sufficient liquidity for its operational and strategic needs.

The Annual General Meeting held on 12 May 2026 authorized the Board of Directors to resolve on a rights issue of up to 14,600,000 new shares. The bridge facility is intended to be repaid with the proceeds from the planned rights offering of up to EUR 80 million.

In addition company has a EUR 20 million revolving credit facility in use for general corporate purposes, of which EUR 19 million has been drawn.

Visionix acquisition

Revenio signed an agreement in April 2026 to acquire French LT International SAS, the parent company of the Visionix International Group ("Visionix"). The acquisition was completed at the end of May 2026. The debt-free, cash-free value of the transaction (enterprise value) was EUR 290 million. The purchase price paid to the sellers was EUR 250 million, of which EUR 55.7 million (2,485,797 new shares at the agreed price of EUR 22.40 per share) was paid in shares. In the IFRS financial statements the share consideration is measured at fair value at the acquisition date, amounting to EUR 33.4 million (EUR 13.44 per share).

The two companies are joining forces and creating a leading turnkey solutions provider in the global eye care market with more than EUR 250 million in sales, EUR 45 million in adjusted EBITDA and over 800 employees (combined illustrative figures 2025).

Joining forces with Visionix represents a significant milestone in the execution of Revenio's growth strategy, expanding Revenio's offering with a highly complementary product and software portfolio, including optical coherence tomography (OCT) equipment – a strategically important and previously untapped segment for Revenio. Furthermore, it combines Revenio's strong position in ophthalmic diagnostics and software under the iCare brand with Visionix's broad capabilities in diagnostic, screening, refraction, and finishing solutions. With very limited product overlap and strong commercial complementarity, the transaction creates the foundation for a broader and more integrated eye care offering.

Leveraging a significantly expanded and highly complementary portfolio, the combined entity is positioned as a leading turnkey solutions provider across optical retail, optometry and ophthalmology. With greater scale, portfolio breadth and channel reach, the combined entity is even better positioned to compete in the eye care market. Altogether, the transaction brings together two highly complementary businesses, enabling accelerated growth and value creation with greater scale and synergies.

Pro Forma financial information

On May 28, 2026, Revenio Group Oyj completed the acquisition of LT International SAS, the parent company of the Visionix International Group (the "Visionix Transaction"). To illustrate the effects of the Visionix Transaction and related financing on Revenio's financial information and to facilitate comparability, Revenio presents unaudited pro forma financial information in this half-year report.

The unaudited pro forma financial information has been prepared to illustrate how the Visionix Transaction and related financing would have affected Revenio's consolidated income statement had they been completed on 1 January 2025.

The pro forma financial information is presented for illustrative purposes only. The unaudited pro forma financial information does not purport to represent what Revenio's results of operations would have been had the Visionix Transaction and related financing been completed on the date assumed, nor is it indicative of expected future results of operations.

The pro forma financial information does not reflect potential cost savings, synergy benefits, revenue enhancements or future integration costs that may result from the Visionix Transaction.

Pro forma key figures

EUR million, unless otherwise indicated	1-6/2026	1-12/2025
Net sales	121.9	252.8
Gross margin	73.4	152.9
Gross margin-%	60.3%	60.5%
EBITDA	16.2	35.7
EBITDA-%	13.3%	14.1%
ADJUSTED EBITDA	17.4	45.3
Adjusted EBITDA-%	14.3%	17.9%
EBITA	13.4	29.8
EBITA-%	11.0%	11.8%
Adjusted EBITA	14.6	39.3
Adjusted EBITA-%	12.0%	15.6%
Operating profit	9.2	21.6
Operating profit-%	7.6%	8.5%
Adjusted operating profit	10.5	31.1
Adjusted operating profit-%	8.6%	12.3%
Profit before taxes	9.7	9.5
Profit before taxes-%	7.9%	3.8%
Profit for the period	6.0	4.3
Profit for the period-%	4.9%	1.7%

More detailed pro forma financial information and the basis of preparation are presented in Appendix 1 to this half-year report.

Administration

Personnel and management

On June 30, 2026, the members of Revenio Group's Leadership Team were:

- CEO Jouni Toijala
- Vice President, U.S. Sales John Floyd
- Vice President, Quality Heli Huopaniemi
- Vice President, Operations Ari Isomäki
- Interim CFO Juha Jaatinen
- Vice President, R&D Haniel Abitbol
- Vice President, Products Erkki Tala
- Vice President, Strategy and Business Development Mari Korhonen
- Vice President, People & Culture Hanna Vuornos
- Vice President, International Sales Umberto Bargiggia
- Vice President, Marketing Jussi Nevanlinna

Average number of personnel during the review period

	1-6/2026	1-6/2025	1-12/2025
Revenio Group	332	248	248

At the end of the review period, the number of employees was 765 (251).

The Board of Directors

Until the Annual General Meeting held on May 12, 2026, the members of the Company's Board of Directors were Arne Boye Nielsen (Chair), Bill Östman (Vice Chair), Heli Lindfors, Anat Loewenstein, Riad Sherif, Ann-Christine Sundell and Pekka Tammela.

As of the Annual General Meeting, the members of the Company's Board of Directors were Arne Boye Nielsen (Chair), Bill Östman (Vice Chair), Heli Lindfors, Anat Loewenstein and Riad Sherif.

As of May 28, 2026, the Company's Board of Directors comprises Arne Boye Nielsen (Chair), Bill Östman (Vice Chair), Marc Abitbol, Nicklas Hansen, Heli Lindfors, Anat Loewenstein, Riad Sherif and Charles Vilgrain.

Audit Committee

At its organizing meeting, held after the Annual General Meeting 2026, the Board elected from amongst its members the following members to serve on its Audit Committee: Heli Lindfors (Chair), Arne Boye Nielsen and Bill Östman. The Board updated the composition of the Audit Committee on June 10, 2026 and elected Nickas Hansen as a member of the Audit Committee. Bill Östman stepped down from his position as a member.

Remuneration Committee

At its organizing meeting, held after the Annual General Meeting 2026, the Board elected from amongst its members the following members to serve on its Remuneration Committee: Bill Östman (Chair), Riad Sherif and Arne Boye Nielsen.

Integration Committee

The Board of Directors appointed the following members from among its members to the Integration Committee: Marc Abitbol (Chair), Nicklas Hansen, Arne Boye Nielsen and Charles Vilgrain.

Technology Committee

The Board of Directors appointed the following members from among its members to the Technology Committee: Marc Abitbol (Chair), Anat Loewenstein and Bill Östman.

Auditor

At the Annual General Meeting 2026 Deloitte Oy, Authorized Public Accountants, was re-elected as the Company's auditors, with Mikko Lahtinen, Authorized Public Accountant, as the principal auditor. The Auditor's Fee is to be paid upon as invoiced and approved by the company.

Shares, share capital, and management and employee holdings

On June 30, 2026, Revenio Group Corporation's fully paid-up share capital registered with the Trade Register was EUR 5,314,918.72 and the number of shares totaled 29,166,913. The Company has one class of shares, and all shares confer the same voting rights and an equal right to dividends and the Company's funds.

The Annual General Meeting of May 12, 2026, decided that approximately 40% of Board members' emolument will be settled in the form of Company shares. The shares will be transferred to the members of the Board within two weeks of the publication of Revenio Group Oyj's half-year financial report for the period 1 January–30 June 2026, using as the value of the share the volume-weighted average trading price on the day following the publication of the half-year financial report.

The Company did not buy back any of its shares during the review period. At the end of the review period, the Company held 75,850 of its own shares.

On June 30, 2026, the President & CEO, members of the Board of Directors, the Leadership team members, and their related parties held 1.60% of the Company's shares, or 468,046 shares.

The valid authorizations of the Board of Directors relating to repurchase and issuance of shares are presented in the section on the Annual General Meeting.

Share incentive plans

Revenio Group Corporation's Board of Directors has decided on the three-year performance periods of the performance-based long-term share-based incentive plans for the company's key personnel, that are effect during the financial year 2026, on March 2024 (PSP 2024-2026) and May 2025 (PSP 2025-2027). Long-term performance-based share plans form part of the Company's remuneration program for key personnel and are aimed at supporting the implementation of the Company's strategy and harmonizing the objective of key personnel and Company shareholders in growing shareholder value.

The Board of Directors decided in June 2026 on the commencement of a new three-year performance period of the long-term performance-based share plan (PSP 2026-2028) for the company's CEO. The performance measures based on which the potential share rewards under PSP 2026-2028 will be paid is increase of the company's market capitalization. If all the performance targets set are fully achieved, the aggregate maximum number of shares to be paid based on this plan is approximately 25 000 shares. This number of shares represents gross earnings, from which the portion required to cover the taxes arising from the share plan and other possible applicable tax-related payments is deducted, which is paid in cash. In practice, about 40% of the total number of shares is paid in shares and about 60% in cash to cover taxes and other possible tax-related payments.

The Board of Directors of Revenio Group Corporation decided on the establishment of a new individual restricted share plan structure (RSP 2026-2028) which is intended to be used as a complementary share-based retention plan for the Group's Leadership Team and other selected key personnel. RSP 2026-2028 comprises a restriction period with an overall length of two year extending to H1 of 2028. During the plan period the company may grant share rewards of fixed amount to individually selected key employees. The aggregate maximum number of shares payable as a reward based on RSP 2026-2028 is approximately 175 000 shares.

The total earnings for 2025 of the individuals participating in the restricted share-based incentive plan (RSP 2024–2026), launched by a decision of the Board of Directors in March 2024, corresponded to 4,606 shares. After taxes and other possible tax-related charges, a total of 1,841 treasury shares will be transferred in a directed share issue without payment.

Information on the remuneration schemes currently used in Revenio Group can be found at the Company's website at:
www.reveniogroup.fi/en/investors/corporate_governance/remuneration

Directed share issue to the sellers

The Annual General Meeting held on May 12, 2026, authorized the Board of Directors to decide on a directed share issue against consideration in which Visionix sellers in the transaction are entitled to subscribe for new shares in the company in deviation from the shareholders' pre-emptive subscription right. Revenio's new shares were registered in the Trade Register on May 29, 2026. Trading in the new shares commenced on the official list of Nasdaq Helsinki Ltd on June 1, 2026. Following the registration of the new shares, the total number of Revenio's shares increased from 26,681,116 to 29,166,913 shares. The new shares represent approximately 8.5% of the company's share capital following the registration of the new shares.

The Board of Directors resolved under the authorization granted by the General Meeting held on May 12, 2026, on a directed share issue to the Visionix sellers in the transaction, in which 2,485,797 new shares in Revenio were issued and subscribed for by the sellers. The shares were subscribed at a share price of EUR 22.40, corresponding to EUR 55.7 million. The subscription price was determined in the negotiations between the company and the sellers as part of the negotiations of the terms of the transaction and the share purchase agreement. The new shares were paid as a contribution in kind by delivering shares in Visionix to Revenio. As the new shares were issued as part of the purchase price relating to a strategically significant acquisition for Revenio, the Board of Directors considered there was a weighty financial reason for deviation of the shareholders' pre-emptive subscription right. The subscription price was recorded in Revenio's reserve for invested unrestricted equity.

Post-completion rights issue

The Annual General Meeting held on May 12, 2026, authorized the Board of Directors to resolve on a share issue against consideration in accordance with the shareholders' pre-emptive rights (rights issue) in one or several tranches so that a maximum number of 14,600,000 new shares in the company may be issued under the authorization, subject to the closing of the transaction.

Revenio has engaged Nordea to act as a global coordinator in the planned EUR 80 million post-completion rights issue. William Demant Invest, owning 6,532,461 shares in Revenio, and sellers representing 2,485,797 shares (after receiving the new shares as a purchase price consideration), together representing approximately 30.92% of Revenio shares post-completion, have irrevocably committed to subscribe pro rata for shares in the planned rights issue. The remainder of the rights issue will be underwritten by Nordea, subject to customary terms and conditions. The proceeds from the rights issue will be used for the repayment of the outstanding bridge facility related to the transaction. The rights issue is targeted to be arranged during mid to late H2/2026.

Flagging notifications

Between January 1–June 30, 2026, Revenio Group Corporation received one notification of any changes in holdings as referred to in Chapter 9, Section 5, of the Securities Markets Act. According to the notification, the total number of Revenio Group Corporation shares owned by Caravelle Capital SAS increased to over five (5) per cent of the share capital of Revenio Group Corporation.

Management transactions

Transactions in Revenio securities by members of Revenio Group Corporation's management during the review period have been published as stock exchange releases and can be viewed on the Company website at: **www.reveniogroup.fi/en/releases**.

Trading on Nasdaq Helsinki

During the period January 1–June 30, 2026, Revenio Group Corporation's share turnover on the Nasdaq Helsinki exchange totaled EUR 124.1 (69.8) million, representing 7.5 (2.6) million shares or 25.8 (9.8) % of all shares outstanding. The highest transaction price was EUR 23.40 (31.88) and the lowest was EUR 12.08 (21.35). The closing price at the end of the review period was EUR 12.20 (27.70) and the weighted average price for the review period was EUR 16.50 (26.65). Revenio Group Corporation's market value stood at EUR 355.8 (739.0) million on June 30, 2026.

Risks and uncertainties

Risks Revenio Group is exposed to include strategic, operational, business cycle, damage, financial, and political risks. In addition, the threat of the global impact of pandemics, climate changes and the risk of cyber threats have increased.

The Group's strategic risks include competition in all sectors, the threat posed by new competing products, and any other actions of the Company's rivals that may affect the competitive situation. Another strategic risk is related to the ability to shift the strategic focus towards integrated and predictive eye care pathways and to succeed in R&D activities and to maintain a competitive product mix. The Group develops new technologies and any failure in the commercialization of individual development projects may result in the depreciation of capitalized development expenses, with an impact on the result. Strategic risks in the Group's segments that require special expertise are also associated with the successful management and development of key human resources and the management of the subcontractor and supplier network. Strategic risks and the need for action are regularly monitored and assessed in connection with day-to-day management, monthly Group reporting, and annual strategy updates.

In terms of risks related to the operating environment, the range and likelihood of cyber threats have increased. When realized, a cyber threat can affect the continuity of Revenio Group's business, the Group's reputation, or lead to significant sanctions. Risks caused by cyber threats are prepared with technical, administrative and organizational information security development. Climate change is associated, for example, with an increase in extreme weather events, rising global temperatures, and sea level rise. The risks arising from these factors for the Group's business may include, among other things, disruptions in the supply chain. Moreover, global pandemics could have direct and indirect effects on Revenio Group's business, including an increased risk of personnel being incapacitated. Government-mandated closures of factories or borders may weaken Revenio Group's operating environment and restrictions on the movement of people could hamper the sales and delivery of Revenio's products.

Corporate acquisitions and the purchase of assets with growth potential related to eye health are part of the Group strategy. The success of these acquisitions has a significant impact on the achievement of growth and profitability targets. Acquisitions may also change the Group's risk profile. The Visionix transaction was completed on 28 May 2026. Revenio's ability to achieve the expected benefits from the Visionix transaction depends to a large extent on the timely and effective integration of Visionix's business, operations, technologies, products and personnel into Revenio's existing business.

Operational risks are associated with the retention and development of major customers, the operations of the distribution network, and success in extending the customer base and markets. Operational risks in the eye health sector that the Company specializes in include, in particular, factors related to expansion into new markets, such as various countries' national regulations of marketing authorizations for medical instruments and the related official decisions concerning the health care market. Success in eye health R&D projects launched in accordance with the strategy can also be classified as an operational risk. Furthermore, the global availability challenges related to electronic components may cause operational risks.

The operational risks related to the manufacture, product development, and production control of medical instruments are estimated to be higher than average due to the sector's ambitious requirements concerning quality. Damage-related risks are covered by insurance. Property and business interruption insurance provides protection against risks in these areas. The business activities of the Group are covered by international liability insurance.

Financial risks can be further categorized into credit, interest-rate, liquidity, and foreign exchange risks. The Board assesses financial risks and other financial matters in its monthly meetings, or more frequently, as necessary. If required, the Board provides decisions and guidelines for the management of financial risks including, for example, interest-rate and currency hedging decisions. Liquidity risk can be affected by the availability of external financing, the development of the Group's credit standing, trends in business operations, and changes in the payment behavior of customers. Liquidity risks are monitored by means of cash forecasts, which are drawn up for periods of, at most, 12 months at a time.

Risks related to corporate responsibility are managed as part of the company's risk management process. Corporate responsibility is viewed through economic, environmental and social responsibility.

Revenio Group offers eye health diagnostics solutions under the iCare and Visionix brand. Reputational damage might have a negative impact on Revenio Group's business. Possible causes for reputational damage include cyber security or compliance challenges or notable delivery or product quality issues. Leakage of sensitive employee or customer data might also lead to reputational damage and notable financial consequences.

Revenio Group products are sold in nearly 130 countries. Economic and political uncertainties, interest and inflation risks and the unstable trade and geopolitical situation may affect the demand for Revenio Group products. Revenio actively monitors political developments in different market areas from a risk management perspective. Developments in national government policies or changes to relevant legislation may have an impact on the Group's business.

Annual General Meeting and currently valid authorizations of the Board of Directors

Decisions by the Annual General Meeting of Revenio Group Corporation on 12 May, 2026

Board and Auditors and remuneration

The AGM decided that eight (8) members be elected to the Board of Directors, of which three (3) shall be elected conditionally so that their terms of office shall commence only after both of the following conditions have been fulfilled:

- The completion (closing) of the acquisition announced by stock exchange release on April 13, 2026, in which the company acquires the entire share capital of the French company LT International SAS, the parent company of the Visionix International group ("Visionix"); and
- The registration of the amendment to the Articles of Association in the Trade Register.

Arne Boye Nielsen, Anat Loewenstein, Heli Lindfors, Riad Sherif, and Bill Östman were re-elected as members of the Board of Directors. Nicklas Hansen, Marc Abitbol and Charles Vilgrain were elected as conditional new members of the Board of Directors as stated above.

In the organizing meeting of the Board of Directors held after the AGM, the Board of Directors elected Arne Boye Nielsen as Chair of the Board and Bill Östman as Vice Chair of the Board. The Board of Directors also decided the members of Audit Committee and elected Heli Lindfors, Arne Boye Nielsen and Bill Östman. The Board of Directors elected Heli Lindfors as Chair of the Audit Committee. The Board of Directors also decided the members of Nomination and Remuneration Committee and elected Bill Östman, Riad Sherif and Arne Boye Nielsen. The Board of Directors elected Bill Östman as Chair of the Nomination and Remuneration Committee.

The AGM decided annual remuneration be paid to the members of the Board of Directors for the term of office ending at the close of the Annual General Meeting 2027 as follows: EUR 70,000 to the Chair of the Board, EUR 45,000 to any Vice Chair of the Board, EUR 35,000 to the members of the Board, EUR 15,000 to the Chair of the Audit Committee, EUR 10,000 to the Chair of the Nomination and Remuneration Committee, and EUR 5,000 to the members of the Board committees. In addition to the above, the Chair of a potentially established Technology Committee EUR 10,000 and its members EUR 5,000, as well as the Chair of a potentially established Integration Committee EUR 20,000 and its members EUR 5,000.

Approximately 40 per cent of the annual remuneration (gross) is to be paid in shares of the company by transferring treasury shares held by the company, however not exceeding a total of 11,200 shares, and the remaining approximately 60 per cent be paid in cash. From the cash portion, tax will be withheld, calculated on the basis of the full amount of the annual remuneration. The shares will be transferred to the members of the Board within two weeks of the publication of Revenio Group Oyj's half-year financial report for the period 1 January–30 June 2026, using as the value of the share the volume-weighted average trading price on the day following the publication of the half-year financial report.

The AGM further decided that the Chairs of the Board and the committees be paid an attendance allowance of EUR 1,000 for Board and the committee meetings and EUR 600 for short remote meetings, and to the members of the Board in the amount of EUR 600 per meeting for meetings of the Board and the committees and EUR 300 per short remote meeting. However, for Chairs of the Board and the committees who reside outside Finland and travel to Finland to attend meetings, the meeting fee for meetings of the Board and the committees shall be EUR 2,000, and for members of the Board the meeting fee for meetings of the Board and the committees shall be EUR 1,200.

Any travel expenses incurred by the members of the Board and the committees shall be reimbursed in accordance with the company's travel policy.

The AGM also decided that the Board remuneration be paid in accordance with to those members conditionally elected to the Board, provided that their term of office begins within one month of the resolution of the General Meeting. If the term of office begins thereafter, the annual remuneration will be paid in proportion to the length of their term of office compared to that of the other members of the Board, using 12 months as the time basis for the determination of annual remuneration. If the term of office of such Board members begins later than two weeks after the publication of Revenio Group Oyj's half-year financial report for the period 1 January–30 June 2026, the portion of the remuneration payable in shares shall be transferred to them within two weeks of the commencement of their term of office.

The AGM re-elected Deloitte Ltd, Authorized Public Accountants, as the company's auditors, with Authorized Public Accountant (APA) Mikko Lahtinen acting as the principal auditor. The AGM decided to pay the auditors' fees as invoiced and approved by the company.

Annual profit distribution, dividend distribution and capital repayment

The AGM decided to accept the Board's proposal on profit distribution, according to which no dividend for the financial year 2025 will be paid.

Authorizing the Board of Directors to decide on the acquisition of own shares

The AGM authorized the Board of Directors to resolve on the acquisition of a maximum of 1,334,055 of the company's own shares in one or more tranches using the company's unrestricted equity.

The company may buy back shares in order to develop its capital structure, finance or implement any corporate acquisitions or other transactions, implement share-based incentive plans, pay board fees or otherwise transfer or cancel them.

The company may buy back shares in public trading on marketplaces whose rules and regulations allow the company to trade in its own shares. In such a case, the company buys back shares through a directed purchase, i.e. in a proportion other than its shareholders' holdings of company shares, with the consideration paid for the shares based on their publicly quoted market price so that the minimum price of the purchased shares equals the lowest market price quoted in public trading during the authorization period and their maximum price equals the highest market price quoted in public trading during that period.

The authorization is effective until the end of the Annual General Meeting held in 2027, yet no further than until June 30, 2027. This authorization shall supersede the authorization granted at the Annual General Meeting of April 10, 2025.

Authorizing the Board of Directors to decide on a share issue and on granting stock options and other special rights entitling to shares

The AGM decided to authorize the Board of Directors to decide on issuing a maximum of 2,668,111 shares in a share issue or by granting special rights (including stock options) entitling holders to shares as referred to in Chapter 10 Section 1 of the Companies Act, in one or several tranches.

This authorization is to be used to finance and implement any prospective corporate acquisitions or other transactions, to implement the company's share-based incentive plans, or for other purposes determined by the Board.

The authorization grants the Board the right to decide on all terms and conditions governing the share issue and the granting of said special rights, including on the recipients of the shares or special rights and the amount of payable consideration.

The authorization also includes the right to issue shares by deviating from the shareholders' pre-emptive rights, i.e. by issuing them in a directed manner. The authorization of the Board covers both the issue of new shares and the transfer of any shares that may be held by the company.

The authorization is effective until the end of the Annual General Meeting held in 2027, yet no further than until June 30, 2027. This authorization shall supersede the issue authorization granted at the Annual General Meeting of April 10, 2025.

The share issue authorizations related to the Visionix acquisition (the "Transaction") announced by the Company on 13 April 2026

a) Authorising the Board of Directors to decide on a directed share issue

The AGM decided to authorize the Board of Directors to decide on a directed share issue against consideration in which sellers in the Transaction are entitled to subscribe for new shares in the company in deviation from the shareholders' pre-emptive subscription right (directed share issue). There is a weighty financial reason for deviation of the shareholders' pre-emptive subscription right as the shares will be issued as part of the purchase price relating to a strategically significant acquisition for the company.

The new shares can be paid by contributing assets to the company (i.e., the sellers' shares and other securities in the Transaction) in accordance with the SPA (contribution-in-kind). A maximum number of 2,485,797 new shares may be issued in the directed share issue. The Board of Directors is authorized to decide on all the other terms and conditions of the share issue.

The authorization is effective until December 31, 2026. The authorization does not revoke other share issue authorizations resolved in the Annual General Meeting. On May 28, 2026 the Board of Directors decided on a directed share issue to the sellers in the transaction, in which 2,485,797 new shares in Revenio were issued and subscribed for by the sellers. The shares were subscribed at a share price of EUR 22.40, corresponding to EUR 55.7 million. The subscription price was determined in the negotiations between the company and the sellers as part of the negotiations of the terms of the transaction and the share purchase agreement. The new shares were paid as a contribution in kind by delivering shares in Visionix to Revenio. As the new shares were issued as part of the purchase price relating to a strategically significant acquisition for Revenio, the Board of Directors considered there was a weighty financial reason for deviation of the shareholders' pre-emptive subscription right. The subscription price was recorded in Revenio's reserve for invested unrestricted equity.

b) Authorizing the Board of Directors to decide on a rights issue

The AGM decided to authorize the Board of Directors to resolve on a share issue against consideration in accordance with the shareholders' pre-emptive rights (rights issue) in one or several tranches so that a maximum number of 14,600,000 new shares in the company may be issued under the authorization, subject to the closing of the Transaction. The number of shares covered by the authorization has been determined taking into account the share issue authorization in section 19 a) (Authorising the Board of Directors to decide on a directed share issue) above.

The Board of Directors is authorized to decide on all the other terms and conditions of the share issue and the Board of Directors has the right to resolve to offer the shares not subscribed by shareholders pursuant to their pre-emptive subscription right for other shareholders or other parties decided by the Board of Directors.

The authorization is proposed to be effective until June 30, 2027. The authorization does not revoke other share issue authorizations resolved in the Annual General Meeting.

Major shareholders on June 30, 2026*

		No. of shares	%
1	William Demant Invest A/S	6,657,461	22.83%
2	Caravelle Capital SAS	1,522,754	5.22%
3	Danske Invest	850,818	2.92%
4	Vanguard	836,839	2.87%
5	Ilmarinen Mutual Pension Insurance Company	763,118	2.69%
6	SEB Funds	724,815	2.62%
7	Nordea Funds	523,823	1.80%
8	BlackRock	468,238	1.61%
9	Varma Mutual Pension Insurance Company	446,166	1.53%
10	Marc Abitbol	440,945	1.51%

* Monitor by Modular Finance AB. Compiled and processed ownership data from various public sources, including Euroclear Finland and Morningstar, and from direct shareholder disclosures. While all efforts have been made to secure as updated and complete information as possible, neither Modular Finance nor Revenio Group can guarantee the completeness or accuracy of the data.

Alternative key figures used in financial reporting

Revenio Group Corporation has adopted the guidelines of the European Securities and Market Authority (ESMA) on Alternative Performance Measures. In addition to the IFRS-based key figures, the Company will publish certain other generally used key figures that may, as a rule, be derived from the income statement and balance sheet. The calculation of these figures is presented below. According to the Company's view, these key figures supplement the income statement and balance sheet, providing a better picture of the company's financial performance and position.

Revenio Group's reported net sales are strongly affected by fluctuations in the exchange rate between the euro and the US dollar. As an alternative key figure, the Company also presents net sales with the exchange rate effect eliminated.

Key figures

MEUR	4-6/2026	4-6/2025	1-6/2026	1-6/2025	1-12/2025
Net sales	39.3	26.5	66.6	52.6	109.7
Gross margin	25.4	19.3	44.1	38.2	77.8
Gross margin-%	64.7	72.6	66.2	72.6	70.9
EBITDA	4.3	7.2	7.8	15.0	29.9
EBITDA-%	10.9	27.3	11.7	28.4	27.3
Operating profit	2.4	6.1	4.8	12.7	25.4
Operating profit-%	6.1	23.0	7.2	24.2	23.2
Profit before taxes	2.2	4.4	5.5	10.0	22.8
Profit before taxes-%	5.7	16.8	8.3	19.0	20.8
Profit for the period	0.6	3.1	3.0	7.3	17.4
Profit for the period-%	1.5	11.6	4.6	13.8	15.9
Gross capital expenditure	8.9	0.9	9.6	1.4	4.3
Gross capital expenditure-%	22.5	3.2	14.4	2.6	3.9
R&D costs	9.1	2.6	12.2	5.2	11.6
R&D costs-% from net sales	23.1	9.8	18.3	9.9	10.5
Gearing-%	159.2	-1.3	159.2	-1.3	-13.3
Equity ratio-%	31.2	77.2	31.2	77.2	76.1
Return on investment-% (ROI)	1.2	4.3	2.5	9.5	20.8
Return on equity-% (ROE)	0.5	2.9	2.3	6.9	15.7
Earnings per share, EUR	0.020	0.116	0.112	0.273	0.655
Equity per share, EUR	5.13	3.91	5.13	3.91	4.30
Average no. of employees	418	249	332	248	248
Cash flow from operating activities	-2.4	6.7	-5.8	11.4	30.2
Cash flow from investing activities	-167.6	-0.8	-168.6	-1.5	-5.2
Net cash used in financing activities	165.5	-12.1	164.1	-13.5	-16.6
Total cash flow	-4.5	-6.2	-10.4	-3.6	8.4

Formulas

KEY FIGURE	PURPOSE	DEFINITION
Gross margin	Describes the margin after deducting direct material and services costs	Net sales – materials and services
Gross capital expenditure	Indicates the amount of investments made in assets that generate future cash flows	Investments in tangible and intangible assets + investments in other non-current assets + change in fair value of non-current assets + change in non-current receivables
R&D costs	Describes investments in the development of future products and technologies	Development expenses recognized as costs + capitalized development expenses
Return on investment (ROI)	Measures the return on invested capital	(Pre-tax profit + Finance costs) / Invested capital (average)
Return on equity (ROE)	Measures the return on capital invested by shareholders.	Profit for the financial year / Equity (average)
Equity ratio	Assesses solvency by measuring the proportion of equity relative to total assets	Equity / Total assets
Net leveraging (gearing)	Describes the debt burden relative to equity, taking cash assets into account	(Interest-bearing liabilities – Cash and cash equivalents) / Equity
Net debt / Adjusted EBITDA	Describes the debt burden relative to company's profitability	(Interest-bearing liabilities – Cash and cash equivalents) / (EBITDA 12 months + non-recurring items 12 months)
Equity attributable to equity owners of the parent company per share	Describes the amount of equity per share	Equity / Number of shares
Growth in net sales, adjusted by the effect of exchange rates	Describes organic revenue growth excluding the effects of exchange rate changes	(Net sales excluding exchange rate effects – Net sales in the comparison period) / Net sales in the comparison period
Adjusted operating profit (EBIT)	Presents operating profit excluding one-off items	Operating profit + non-recurring items
Earnings before interest, taxes and amortization, EBITA	Describes the company's operating performance before amortization and financial items	Operating profit + Amortization
Adjusted EBITA	Presents EBITA excluding one-off items.	EBITA + non-recurring items
EBITDA	Describes the company's operating performance before depreciation, amortization and financial items.	Operating profit + Depreciation and amortization

MEUR, unless otherwise specified

EBITDA	**1-6/2026**	**1-6/2025**
Operating profit	4.8	12.7
Depreciation and amortization	3.0	2.2
EBITDA	7.8	15.0

GROSS CAPITAL EXPENDITURE	**1-6/2026**	**1-6/2025**
Investments in tangible assets	0.8	0.4
Investments in intangible assets	2.0	1.1
Investments in other non-current assets	4.1	0.0
Change in fair value of non-current assets	0.0	0.0
Change in non-current receivables	2.6	-0.1
Gross capital expenditure	9.6	1.4

R&D COSTS	**1-6/2026**	**1-6/2025**
Development expenses recognized as other operating expense	3.4	1.1
Development expenses recognized as employee benefit expense	7.4	3.1
Capitalized development expenses	1.4	1.0
R&D costs	12.2	5.2

RETURN ON INVESTMENT (ROI)	**1-6/2026**	**1-6/2025**
Invested capital (equity + interest-bearing liabilities) average	267.5	119.4
Pre-tax profit	5.5	10.0
Finance costs	1.3	1.3
Return on investment (ROI)	2.5%	9.5%

RETURN ON EQUITY (ROE)	**1-6/2026**	**1-6/2025**
Profit for the period	3.0	7.3
Equity (average)	132.1	106.1
Return on equity (ROE)	2.3%	6.9%

EQUITY RATIO	**1-6/2026**	**1-6/2025**
Equity	149.5	104.4
Total assets	479.2	135.2
Equity ratio	31.2%	77.2%

NET LEVERAGING (GEARING)	**1-6/2026**	**1-6/2025**
Interest-bearing liabilities	255.7	12.7
Cash and cash equivalents	17.8	14.0
Equity	149.5	104.4
Net leveraging (gearing)	159.2%	-1.3%

EQUITY ATTRIBUTABLE TO EQUITY OWNERS OF THE PARENT COMPANY PER SHARE	1-6/2026	1-6/2025
Equity	149.5	104.4
Number of shares (1.000 pcs)	29.2	26.7
Equity attributable to equity owners of the parent company per share (EUR)	5.13	3.91

GROWTH IN NET SALES, ADJUSTED BY THE EFFECT OF EXCHANGE RATES	1-6/2026	1-6/2025
Reported net sales	66.6	52.6
Effect of exchange rates on net sales	1.4	0.4
Net sales adjusted by the effect of exchange rates	68.0	53.0
Growth in net sales, adjusted by the effect of exchange rates	28.8%	9.6%
Reported net sales growth	26.6%	7.2%
Difference, % points	2.2%	2.3%

ADJUSTED OPERATING PROFIT	1-6/2026	1-6/2025
Operating profit, EBIT	4.8	12.7
Non-recurring items	6.9	0.5
Adjusted operating profit, EBIT	11.7	13.2

EARNINGS BEFORE INTEREST, TAXES AND AMORTIZATION	1-6/2026	1-6/2025
Operating profit	4.8	12.7
Amortization of intangible assets	1.3	0.9
Earnings before interest, taxes and amortization, EBITA	6.1	13.6
Earnings before interest, taxes and amortization, EBITA %	9.2%	25.8%

ADJUSTED EARNINGS BEFORE INTEREST, TAXES AND AMORTIZATION	1-6/2026	1-6/2025
Earnings before interest, taxes and amortization, EBITA	6.1	13.6
Non-recurring items	6.9	0.5
Adjusted earnings before interest, taxes and amortization, EBITA	13.0	14.0
Adjusted earnings before interest, taxes and amortization, EBITA %	19.5%	26.7%

GROSS MARGIN	1-6/2026	1-6/2025
Net sales	66.6	52.6
Materials and services	22.5	14.4
Gross margin	44.1	38.2

NET DEBT / ADJUSTED EBITDA	1-6/2026	1-6/2025
Interest bearing debt	255.7	12.7
Cash and cash equivalents	17.8	14.0
EBITDA	35.5	30.9
Non-recurring items	9.5	0.6
Net debt / Adjusted EBITDA	5.3	-0.04

Half-Year Report January 1–June 30, 2026, tables

Consolidated comprehensive income statement

MEUR	4-6/2026	4-6/2025	1-6/2026	1-6/2025	1-12/2025
NET SALES	39.3	26.5	66.6	52.6	109.7
Other operating income	0.4	0.0	0.5	0.0	0.2
Materials and services	-13.9	-7.3	-22.5	-14.4	-31.9
Employee benefits	-10.1	-6.5	-17.1	-13.2	-26.4
Depreciation, amortization, and impairment	-1.9	-1.1	-3.0	-2.2	-4.5
Other operating expenses	-11.4	-5.5	-19.7	-10.1	-21.7
OPERATING PROFIT	2.4	6.1	4.8	12.7	25.4
Financial income and expenses (net)	-0.3	-1.7	0.6	-2.7	-2.6
Share of the profit or loss of associates accounted for using the equity method	0.1	0.0	0.1	0.0	0.0
PROFIT BEFORE TAXES	2.2	4.4	5.5	10.0	22.8
Income taxes	-1.7	-1.4	-2.5	-2.7	-5.4
PROFIT FOR THE PERIOD	0.6	3.1	3.0	7.3	17.4
Other comprehensive income items	0.3	0.0	0.2	-0.2	-0.2
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	0.8	3.1	3.3	7.1	17.2
Total comprehensive income attributable to:					
Owners of the parent	0.8	3.1	3.3	7.1	17.2
Non-controlling interests	0.0	0.0	0.0	0.0	0.0
Earnings per share, EUR	0.020	0.116	0.112	0.273	0.655

Consolidated balance sheet

MEUR	30.6.2026	30.6.2025	31.12.2025
ASSETS			
NON-CURRENT ASSETS			
Goodwill	184.2	62.8	62.9
Intangible assets	131.2	22.2	23.3
Tangible assets	9.0	2.2	2.1
Right-of-use assets	10.0	4.7	5.0
Other non-current financial assets	4.6	0.4	0.5
Investments accounted for using the equity method	16.3	0.0	0.0
Other receivables	2.9	0.0	0.3
Deferred tax assets	15.9	2.6	3.7
TOTAL NON-CURRENT ASSETS	374.0	95.0	97.8
CURRENT ASSETS			
Inventories	44.8	9.7	10.8
Trade and other receivables	42.6	16.5	15.8
Cash and cash equivalents	17.8	14.0	26.2
TOTAL CURRENT ASSETS	105.2	40.2	52.8
TOTAL ASSETS	479.2	135.2	150.6
SHAREHOLDERS’ EQUITY AND LIABILITIES			
SHAREHOLDERS’ EQUITY			
Share capital	5.3	5.3	5.3
Fair value reserve	-0.4	-0.4	-0.4
Reserve for invested unrestricted capital	85.2	52.0	52.0
Other reserves	0.3	0.3	0.3
Retained earnings	60.7	49.1	59.4
Translation difference	-0.1	-0.3	-0.3
Own shares held by the company	-1.5	-1.6	-1.6
Total equity attributable to owners of the parent	149.5	104.4	114.7
Non-controlling interests	0.0	0.0	0.0
TOTAL SHAREHOLDERS’ EQUITY	149.5	104.4	114.7
LIABILITIES			
NON-CURRENT LIABILITIES			
Deferred tax liabilities	20.7	3.5	3.5
Interest-bearing and other non-current liabilities	121.6	5.0	3.0
Lease liabilities	6.9	3.3	3.6
TOTAL NON-CURRENT LIABILITIES	149.2	11.8	10.2
CURRENT LIABILITIES			
Trade and other payables	46.9	12.8	19.3
Provisions	3.3	0.5	0.8
Interest-bearing current liabilities	127.2	4.2	4.2
Lease liabilities	3.1	1.5	1.5
TOTAL CURRENT LIABILITIES	180.5	19.0	25.8
TOTAL LIABILITIES	329.7	30.8	35.9
TOTAL SHAREHOLDERS’ EQUITY			
AND TOTAL LIABILITIES	479.2	135.2	150.6

Consolidated statement of changes in equity

MEUR	Share capital	Reserve for invested unrestricted equity	Other reserves	Retained earnings	Translation difference	Own shares	Total equity
Shareholders equity 1 Jan 2026	5.3	52.0	-0.1	59.4	-0.3	-1.6	114.7
Dividend distribution	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Issue of share capital	0.0	33.2	0.0	0.0	0.0	0.0	33.2
Disposal and purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other direct entries to retained earnings	0.0	0.0	0.0	-1.7	0.0	0.0	-1.7
Profit for the period	0.0	0.0	0.0	3.0	0.0	0.0	3.0
Other comprehensive income	0.0	0.0	0.0	0.0	0.2	0.0	0.0
Total shareholders equity attributable to owners of the parent	5.3	85.2	-0.1	60.7	-0.1	-1.5	149.5
Non-controlling interests	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity 30 June 2026	5.3	85.2	-0.1	60.7	-0.1	-1.5	149.5

MEUR	Share capital	Reserve for invested unrestricted equity	Other reserves	Retained earnings	Translation difference	Own shares	Total equity
Balance 1 Jan 2025	5.3	52.1	-0.1	52.2	-0.1	-1.7	107.7
Dividend distribution	0.0	0.0	0.0	-10.6	0.0	0.0	-10.6
Disposal and purchase of own shares	0.0	-0.1	0.0	0.0	0.0	0.1	0.0
Other direct entries to retained earnings	0.0	0.0	0.0	0.2	0.0	0.0	0.2
Profit for the period	0.0	0.0	0.0	7.3	0.0	0.0	7.3
Other comprehensive income	0.0	0.0	0.0	0.0	-0.2	0.0	-0.2
Balance 30 June 2025	5.3	52.0	-0.1	49.1	-0.3	-1.6	104.4

Consolidated cash flow statement

MEUR	4-6/2026	4-6/2025	1-6/2026	1-6/2025	1-12/2025
CASH FLOW FROM OPERATIONS					
Profit for the period	0.6	3.1	3.0	7.3	17.4
Adjustments:					
Depreciation, amortization, and impairment	1.9	1.1	3.0	2.2	4.5
Other non-cash items	-0.4	0.6	-0.8	0.9	1.3
Interest and other financial expenses	1.0	1.7	1.2	2.8	3.1
Interest income and other financial income	-0.9	0.0	-1.9	-0.1	-0.6
Taxes	1.7	1.4	2.5	2.7	5.4
Other adjustments	-0.1	-0.1	-0.1	-0.1	-0.1
Change in working capital:					
Changes in sales and other receivables	-2.0	-0.1	-3.3	1.8	1.3
Changes in current assets	1.3	-0.2	0.8	0.4	-0.7
Changes in trade and other payables	-3.1	2.0	-5.9	-2.4	3.5
Change in working capital, total	-3.8	1.8	-8.3	-0.3	4.1
Interest paid	-0.7	-0.1	-0.8	-0.2	-0.4
Interest received	0.0	0.0	0.1	0.0	0.1
Taxes paid	-1.7	-2.7	-3.7	-4.0	-4.6
NET CASH FLOW FROM OPERATING ACTIVITIES	-2.4	6.7	-5.8	11.4	30.2
CASH FLOW FROM INVESTING ACTIVITIES					
Acquisitions of subsidiaries less cash and cash equivalents at acquisition time	-166.5	0.0	-166.5	0.0	0.0
Purchase of tangible assets	-0.5	-0.3	-0.5	-0.4	-1.1
Purchase of intangible assets	-1.3	-0.6	-1.6	-1.1	-3.1
Investments in other receivables	0.7	0.0	0.0	0.0	-1.1
NET CASH FLOW FROM INVESTING ACTIVITIES	-167.6	-0.8	-168.6	-1.5	-5.2
CASH FLOW FROM FINANCING ACTIVITIES					
Repayments of loans	-63.1	-1.1	-64.2	-2.1	-4.2
Proceeds from borrowings	229.0	0.0	229.0	0.0	0.0
Dividends paid	0.0	-10.6	0.0	-10.6	-10.6
Payments of lease agreement liabilities	-0.3	-0.4	-0.7	-0.7	-1.7
NET CASH FLOW FROM FINANCING ACTIVITIES	165.5	-12.1	164.1	-13.5	-16.6
Net change in cash and credit accounts	-4.5	-6.2	-10.4	-3.6	8.4
Cash and cash equivalents at beginning of period	21.4	22.2	26.2	20.7	20.7
Effect of exchange rates	0.8	-2.0	1.9	-3.0	-2.9
Cash and cash equivalents at end of period	17.8	14.0	17.8	14.0	26.2

Notes to the consolidated financial statements

Accounting policies applied in the preparation of the Half-year report

This Half-year report has been prepared in accordance with IAS 34 Interim Financial Reporting. The figures presented in this Half-year report are unaudited.

The Half-year report has been prepared using the same accounting policies as those applied in the Group's financial statements for 2025, except for the additions to the accounting policies and the amendments to existing standards described below. This Half-year report should be read in conjunction with the consolidated financial statements for the financial year ended 31 December 2025.

The Group has applied the following additions to its accounting policies:

Associates are entities over which the Group has significant influence but not control. Associates are accounted for using the equity method. Investments accounted for using the equity method are initially recognized at cost. The consolidated financial statements include the Group's share of the comprehensive income and changes in equity of equity-accounted investees from the date on which significant influence commences until the date on which significant influence ceases.

Derivative contracts used to hedge interest rate risk are initially recognized at fair value on the date the derivative contract is entered into and are subsequently remeasured to fair value at the end of each reporting period. Changes in fair value are recognized in profit or loss and presented within finance income or finance expenses. In the statement of financial position, derivatives are presented within non-current liabilities under financial liabilities. Gains and losses arising from foreign currency hedging instruments are recognized in the same income statement line items as the foreign exchange effects of the hedged items.

The Group has applied the following amendments to existing standards effective from 1 January 2026:

IFRS 9 and IFRS 7 amendments, as well as Annual Improvements to IFRS Accounting Standards, Part 11.

In management's assessment, the adoption of these amendments has not had a material impact on the Group's financial statements.

Key events in January-June 2026

Visionix acquisition

On 28 May 2026, Revenio Group Corporation acquired 100% of the share capital of LT International SAS. LT International SAS is the parent company of the French Visionix International Group. The acquisition significantly expands the Group's product offering and market position. It increases the Group's addressable market by approximately 2.5 times to around USD 2.5 billion and enables accelerated entry into the rapidly growing OCT segment. The combined Group is a leading provider of comprehensive solutions in the global eye care market, with combined revenue of more than EUR 250 million and more than 800 employees (illustrative combined figures for 2025). The acquisition is expected to generate more than EUR 20 million of EBITDA growth through joint value creation and synergies by the end of 2029. Further information and a preliminary purchase price allocation are presented in the section Visionix Acquisition.

Following the completion of the Visionix acquisition on 28 May 2026, the Group has been assessing the impact of the expanded business on its strategy, operating model and segment structure. Since the acquisition, Revenio has focused on advancing the integration process and developing a new combined strategy. The Group will provide an update on its strategy as part of its Capital Markets Day to be held on 15 September 2026.

Revenio also publishes unaudited pro forma financial information regarding the effects of the Visionix acquisition; for further information, see page 39.

Visionix acquisition financing

As part of the Visionix transaction, Revenio carried out a directed share issue to the sellers on 28 May 2026, in which

2,485,797 new Revenio shares were issued and subscribed for by the sellers. Further information is presented in the section Equity.

To finance the Visionix acquisition, the Group entered into a new debt financing arrangement totalling EUR 220 million, arranged by Nordea Bank Abp. The financing consists of a EUR 130 million amortizing term loan (with a maturity of four years and options to extend by up to 12 months), an EUR 80 million bridge facility, and a EUR 20 million revolving credit facility for general corporate purposes and a EUR 17 million vendor loan arrangement. In connection with the arrangement, Revenio repaid its existing bank loans with a nominal amount of EUR 3.8 million as of deal closing and Visionix's bank loans of EUR 58.3 million. Further information is presented in the section Financial Liabilities.

The Annual General Meeting held on 12 May 2026 authorized the Board of Directors to resolve on a rights issue of up to 14,600,000 new shares. The bridge facility is intended to be repaid with the proceeds from the planned rights offering of up to EUR 80 million. The share issue is expected to be carried out during the middle or latter part of the second half of 2026. Revenio's largest shareholder, William Demant Invest, and the sellers, who together represent approximately 30.92% of Revenio's shares following completion of the transaction, have irrevocably committed to subscribe for a number of shares corresponding to their respective ownership interests in the planned rights offering.

Other changes

On May 28, 2026, Revenio Group completed the acquisition of the entire share capital of LT International SAS, the parent company of the Visionix International group ("Visionix").

The Annual General Meeting held on May 12, 2026, conditionally elected Marc Abitbol, CEO of Visionix, Charles Vilgrain, Managing Partner of Caravelle Capital SAS, and Nicklas Hansen, Chief Investment Officer at William Demant Invest A/S to the Board of Directors. The commencement of the terms of office of the persons was subject to the completion of the Visionix transaction.

As a result of the completion of the transaction, Marc Abitbol, Charles Vilgrain, and Nicklas Hansen commenced their term of office on the Board of Directors of Revenio on 28 May 2026. Previously re-elected members of the Board are Arne Boye Nielsen, Bill Östman, Riad Sherif, Anat Loewenstein, and Heli Lindfors.

Following the closing of the transaction, Revenio strengthened its Leadership Team to support the integration and development of the joint organization. The following persons were appointed on May 28, 2026 to Revenio's Leadership Team: Mari Korhonen, Vice President, Strategy & Business Development; Jussi Nevanlinna, Vice President, Marketing; Haniel Abitbol, Vice President, R&D; and Umberto Bargiggia, Vice President, International Sales.

As announced on May 13, 2026, Revenio appointed Jukka Kainulainen as the new permanent Chief Financial Officer and member of the Leadership Team. Kainulainen assumed the position on August 24, 2026. Juha Jaatinen continued as interim CFO until then.

Preliminary Purchase Price Allocation for the Visionix acquisition

The identifiable assets acquired and liabilities assumed have been measured at their acquisition-date fair values. Any excess of the purchase consideration over the identifiable net assets acquired has been recognised as goodwill. The purchase price allocation is preliminary as the determination of the fair values of the identifiable assets acquired and liabilities assumed is still incomplete at the reporting date. In particular, the amounts allocated to intangible assets and the resulting goodwill are provisional. Amounts may be adjusted within 12 months of the acquisition date.

The following table gives the initial fair value of the net assets acquired and the initial goodwill arising from the acquisition at the time of acquisition:

Acquisition cost calculation MEUR	
Acquisition cost during the review period	226.9
Assets	
Non-current assets	
Intangible assets	108.1
Tangible assets	13.0
Deferred tax assets	12.1
Trade and other receivables	2.1
Investments	22.2
Total non-current assets	157.4
Current assets	
Inventories	33.2
Trade and other receivables	23.8
Cash and cash equivalents	10.9
Total current assets	68.0
Total assets	225.4
Liabilities	
Non-current liabilities	
Financial liabilities	58.4
Lease liabilities	4.7
Deferred tax liabilities	17.3
Other non-current liabilities	3.1
Total non-current liabilities	83.5
Current liabilities	
Lease liabilities	1.8
Trade and other payables	33.8
Total current liabilities	35.6
Total liabilities	119.1
Net (liabilities) / assets	106.2
Goodwill	120.6
Purchase consideration	226.9
Cash flow	
Consideration paid during the reporting period	-177.1
Closing cash	10.6
Total cash flow	-166.5

Purchase consideration (MEUR)	
Cash paid	177.1
Ordinary shares issued	33.4
Deferred consideration	16.4
Total purchase consideration	226.9

The fair value of the 2,485,797 shares issued as part of the consideration paid was based on the closing share price on 28 May 2026 of EUR 13.44 per share. Issue costs of EUR 213.7 thousand, which were directly attributable to the issue of the shares, have been netted against the deemed proceeds in reserve for invested unrestricted equity.

Deferred consideration with nominal value of EUR 17,250 thousand falls due for payment one year after the completion of the transaction and has been discounted in purchase consideration.

The fair values of the identifiable assets and liabilities presented above are preliminary and may be adjusted during the purchase price allocation measurement period (up to 12 months from the acquisition date) in accordance with IFRS 3. The Group has engaged external valuation experts to determine the fair values of the identified intangible assets.

The allocation of goodwill has not yet been finalized. The goodwill arises from the acquired company’s market position and broader geographical reach, particularly in the EMEA region and the United States; the synergies expected to result from combining Revenio’s and Visionix’s complementary businesses; the standalone growth prospects of Visionix’s business; its skilled workforce; and the going-concern value of the established business.

Acquisition-related costs

Direct transaction costs amounted to approximately EUR 6.1 million during the six-month period ended 30 June 2026 and were recognized in profit or loss (of which EUR 3.1 million was recognized during the interim period ended 31 March 2026). The costs comprise advisory, legal, due diligence and other expenses directly attributable to the acquisition.

Net sales breakdown

Information about geographical areas

NET SALES, MEUR	4-6/2026	4-6/2025	1-6/2026	1-6/2025	1-12/2025
Finland	0.3	0.3	0.7	0.9	1.7
USA	14.1	12.2	25.7	23.3	53.0
EMEA, LATAM, CAN	20.2	9.7	31.3	18.7	37.0
APAC	4.7	4.3	8.9	9.8	18.0
Total	39.3	26.5	66.6	52.6	109.7

Intangible and tangible assets

Intangible assets

JAN 1 - JUN 30, 2026	Goodwill	Other intangible assets	Total
Acquisition cost Jan 1	62.9	35.3	98.2
Increases during the period	0.0	1.6	1.6
Acquired businesses	120.7	114.0	234.7
Translation differences	0.5	0.2	0.7
Acquisition cost Jun 30	184.2	151.0	335.2
Accumulated depreciation Jan 1	0.0	-12.0	-12.0
Accumulated depreciation of acquired businesses	0.0	-6.3	-6.3
Depreciation during the year	0.0	-1.3	-1.3
Translation differences	0.0	-0.1	-0.1
Accumulated depreciation Jun 30	0.0	-19.8	-19.8
Book value Jun 30	184.2	131.2	315.4
Book value Jan 1	62.9	23.3	86.2

Tangible assets JAN 1 - JUN 30, 2026	Machinery and equipment	Advance payments and purchases in progress	Total
Acquisition cost Jan 1	8.4	0.1	8.4
Increase during the period	0.5	0.2	0.8
Acquired businesses	20.9	0.0	20.9
Translation differences	0.1	0.0	0.1
Decreases during the period	0.0	-0.1	-0.1
Acquisition cost Jun 30	29.9	0.2	30.1
Accumulated depreciation Jan 1	-6.3	0.0	-6.3
Accumulated depreciation of acquired businesses	-14.1	0.0	-14.1
Depreciation during the year	-0.6	0.0	-0.6
Translation differences	-0.1	0.0	-0.1
Accumulated depreciation Jun 30	-21.1	0.0	-21.1
Book value Jun 30	8.8	0.2	9.0
Book value Jan 1	2.1	0.1	2.1

Lease agreements

Right-of-use assets JAN 1 - JUN 30, 2026	Business premises	Cars	Devices	Total
Acquisition cost Jan 1	6.5	1.1	0.2	7.8
Increase during the period	0.1	0.5	0.0	0.6
Acquired businesses	4.2	1.1	0.0	5.3
Translation differences	0.1	0.0	0.0	0.1
Decreases during the period	0.0	-0.4	-0.1	-0.5
Acquisition cost Jun 30	10.8	2.2	0.2	13.2
Accumulated depreciation Jan 1	-2.0	-0.7	-0.1	-2.8
Depreciation during the year	-0.8	-0.2	0.0	-1.0
Translation differences	0.1	0.0	0.0.	0.1
Decreases during the period	0.0	0.4	0.0	0.4
Accumulated depreciation Jun 30	-2.6	-0.6	-0.1	-3.3
Book value Jun 30	8.2	1.7	0.1	10.0
Book value Jan 1	4.5	0.3	0.1	5.0

Equity

Share issue

As part of the arrangements for the Visionix transaction, Revenio carried out a directed share issue to the sellers, in which 2,485,797 new Revenio shares were issued and subscribed for by the sellers. The new shares were paid for through a contribution in kind by transferring shares in Visionix to Revenio. The new shares were registered with the Trade Register on May 29, 2026, and the subscription price was recognized in Revenio's invested unrestricted equity reserve (SVOP) at the share price on the completion date of the transaction.

Changes in the number of shares and their impact on equity	Number of shares	Share capital	Reserve for invested unrestricted equity	Own shares	Total
Jan 1, 2026	26,681,116	5.3	52.0	-1.6	55.8
Transfer of the company's own shares March 17, 2026			-0.0	0.0	0.0
Directed share issue May 28, 2026	2,485,797		33.2		33.2
Jun 30, 2026	29,166,913	5.3	85.2	-1.5	89.0

Dividend

The Annual General Meeting held on May 12, 2026, resolved that no dividend would be distributed for the financial year 2025. In accordance with the terms of the share purchase agreement for the acquisition of Visionix, Revenio has undertaken not to propose the distribution of dividends until the deferred purchase price payable to the sellers has been paid in full. The deferred purchase price falls due for payment one year after the completion of the transaction.

Earnings per share

	JAN 1 – JUN 30, 2026	JAN 1 - JUN 30, 2025	JAN 1 - DEC 31, 2025
Profit for the period	3.0	7.3	17.4
Profit for the period attributable to owners of parent	3.0	7.3	17.4
Weighted average number of outstanding shares during the financial period (own shares deducted), qty	27,069,646	26,602,985	26,603,425
Earnings per share	0.112	0.273	0.655

The Group's interest-bearing debt and derivatives at end of period

Financial instrument	Use	Initial amount	Principal out-standing	Book value	Year when granted
Loan from financial institution	Acquired businesses	130.0	130.0	129.9	2026
Bridge financing	Acquired businesses	80.0	80.0	79.9	2026
Vendor loan	Acquired businesses	17.3	17.3	16.4	2026
Credit facility	Acquired businesses	19.0	19.0	18.9	2026
Interest rate swap	Hedging of interest rate risk	65.0	65.0	0.5	2026

To finance the Visionix acquisition, the Group drew a total of EUR 220 million under the financing agreement in May 2026. The financing consists of a EUR 130 million term loan, an EUR 80 million bridge facility, and a EUR 10 million revolving credit facility for general corporate purposes. In addition, the acquisition includes a EUR 17 million vendor loan arrangement. In addition to the revolving credit facility included in the new financing agreement, the Group has a EUR 10 million revolving credit facility for general corporate purposes, of which EUR 1 million remained undrawn as of 30 June 2026.

The original maturity of the term loan and the revolving credit facility is four years from the signing date of the financing agreement, and each may be extended by 12 months with the lender's consent. The term loan is amortized semi-annually. The bridge facility is a bullet loan. The original maturity of the bridge facility is six months from its drawdown date of 28 May 2026, and it may, at Revenio's option, be extended by up to six months.

Under the financing agreement, the Group is required to use the net proceeds from the rights offering planned to be completed during the second half of 2026 to repay the bridge facility until the bridge facility, together with all accrued interest, fees and expenses, has been repaid in full. If the rights offering has not been completed by 28 May 2027 and the funds committed under the previously announced underwriting commitments have not been received, or evidence thereof has not been provided in accordance with the financing agreement, Nordea shall be entitled to cancel its financing commitments and declare all loans drawn under the financing agreement immediately due and payable.

The financing agreement includes a net leverage covenant, pursuant to which the ratio of the Group's net debt to adjusted EBITDA (as defined in the financing agreement) must not exceed 4.50:1 on the testing dates of 31 December 2026 and 31 March 2027, and 3.50:1 on each quarter-end date thereafter. In accordance with the terms of the financing agreement, the covenant level may be temporarily increased in connection with certain acquisitions.

The financing agreement further contains representations, undertakings and security arrangements customary for financing arrangements of this nature, as well as customary provisions relating to change of control, illegality and sanctions, including mandatory prepayment events and events of default.

Repayments of financial liabilities

In May 2026, Revenio repaid a bank loan as well as a bank loan acquired in connection with the Visionix acquisition, totalling EUR 62.1 million.

Derivative instruments

During the review period, Revenio entered into an interest rate swap with a notional amount of EUR 65 million in relation to the EUR 130 million term loan under the new financing agreement. The interest rate swap is measured at fair value through profit or loss. The fair value of the interest rate swap is determined as the present value of future cash flows, calculated using observable market interest rates. Changes in fair value are recognized in finance income or finance expenses. The interest rate swap is presented in the statement of financial position under non-current financial liabilities.

Classification of financial liabilities

JUN 30, 2026	At fair value through profit or loss	Amortized cost	Book value	Fair value
Interest-bearing non-current liabilities	0.0	125.8	125.8	125.8
Other non-interest bearing non-current liabilities	0.0	2.3	2.3	2.3
Non-current liabilities, derivatives	0.0	0.5	0.5	0.5
Interest-bearing current liabilities	0.0	114.0	114.0	114.0
Trade payables and other non-interest bearing current liabilities	0.0	62.2	62.2	62.2
DEC 31, 2025	**At fair value through profit or loss**	**Amortized cost**	**Book value**	**Fair value**
Interest-bearing non-current liabilities	0.0	5.3	5.3	5.3
Other non-interest bearing non-current liabilities	0.0	1.3	1.3	1.3
Interest-bearing current liabilities	0.0	5.7	5.7	5.7
Trade payables and other non-interest bearing current liabilities	0.0	18.3	18.3	18.3

Maturity analysis of contractual liabilities

JUN 30, 2026	Under 1 year	1-5 Years	Over 5 years	Total cash flow
Trade payables and other non-interest bearing debt	62.2	2.3	0.0	64.5
Lease liabilities	3.1	6.1	0.8	10.0
Interest-bearing debt	110.9	118.6	0.2	229.8
Interest rate swap	0.0	0.5	0.0	0.5

DEC 31, 2025	Under 1 year	1-5 Years	Over 5 years	Total cash flow
Trade payables and other non-interest bearing debt	18.3	0.5	0.0	18.8
Lease liabilities	1.5	3.6	0.0	5.1
Interest-bearing debt	4.3	1.7	0.0	6.0

Related party transactions

The Group's related parties include its management (the Board of Directors, the CEO and the Group Leadership Team) and the companies controlled by them, their family members and companies controlled by the family members, the Group's subsidiaries, associates and joint ventures.

Parent and subsidiary relationships of the group **Jun 30, 2026**	**Domicile**	**Holding**
Parent company Revenio Group Corporation	Vantaa	
Icare Finland Oy	Helsinki	100%
Icare USA Inc	Missouri	100%
CenterVue S.p.A	Padua	100%
Revenio Italy S.R.L	Milan	100%
Revenio Australia Pty Ltd	Melbourne	100%
Icare World Australia Pty Ltd	Melbourne	100%
China iCare Medical Technology Co. Ltd	Shanghai	100%
Thirona Retina B.V.	Nijmegen	100%
LT International SAS	Pont-de-l'Arche	100%
Visionix International SAS	Pont-de-l'Arche	100%
SCI Briot Buchmann	Pont-de-l'Arche	100%
Luneau Technology Operations SAS	Pont-de-l'Arche	100%
Luneau SAS	Pont-de-l'Arche	100%
Visionix Ltd	Jerusalem	100%
Visionix USA Inc	Chicago	100%
Optovue Inc	Chicago	100%
Visionix España S.A.	Barcelona	100%
Visionix Italia S.R.L.	Milan	100%
Visionix Deutschland GmbH	Ratingen	100%
Visionix Portugal Unipessoal LDA	Lisbon	100%
Guangzhou Visionix Medical Technology Ltd	Guangzhou	67%
20/20 Vision Center LLC	New York	21.5%
MingSing	Ningbo	35%

Parent and subsidiary relationships of the group **Dec 31, 2025**	**Domicile**	**Holding**
Parent company Revenio Group Corporation	Vantaa	
Icare Finland Oy	Helsinki	100%
Icare USA Inc	Missouri	100%
CenterVue S.p.A	Padua	100%
Revenio Italy S.R.L	Milan	100%
Revenio Australia Pty Ltd	Melbourne	100%
Icare World Australia Pty Ltd	Melbourne	100%
China iCare Medical Technology Co. Ltd	Shanghai	100%
Thirona Retina B.V.	Nijmegen	100%

Events after the review period

On 31 July 2026, Revenio provided an update on the progress of the Visionix integration and announced organizational changes in its U.S. operations.

On 6 August 2026, Revenio’s iCare and EyeCheq announced a strategic partnership and a minority investment.

On 12 August 2026, Jukka Kainulainen was confirmed to commence his role as Chief Financial Officer on 24 August 2026.

On 17 August 2026, Revenio’s iCare DRSplus was incorporated into an FDA-cleared artificial intelligence solution for diabetic retinopathy screening.

Appendixi 1: Unaudited Pro Forma Financial Information

Basis of preparation

The unaudited pro forma financial information has been prepared based on the historical consolidated financial information of Revenio and the historical consolidated financial information of Visionix, and includes certain pro forma adjustments. The pro forma financial information is presented for illustrative purposes only and addresses a hypothetical situation as if the Visionix Transaction and related financing had been completed on January 1, 2025 for the income statement. Therefore, it is not necessarily indicative of what Revenio’s historical financial performance actually would have been had the Visionix Transaction and related financing been completed as of the date indicated and it does not purport project the operating results of Revenio as of any future date.

The pro forma adjustments include: (i) reclassification of Visionix's income statement from a function-based to a nature-based presentation to align with Revenio's reporting format; (ii) fair valuation adjustments arising from the provisional purchase price allocation, including amortisation of identified intangible assets (customer relationships, technology, brands); (iii) elimination of intercompany transactions between Revenio and Visionix; (iv) adjustments related to transaction costs; and (v) financing adjustments reflecting the new financing arrangements entered into in connection with the Visionix Transaction and refinancing of old loans. The pro forma financial information does not reflect potential cost savings, synergy benefits or future integration costs.

Unaudited Condensed Combined Pro Forma Income Statement

For the six months ended June 30, 2026

MEUR	Revenio historical	Visionix reclassified[1] (note 1)	Transaction (note 2)	Financing (note 3)	Revenio pro forma
Net sales	66.6	55.6	-0.3	-	121.9
Other operating income	0.5	0.0	-	-	0.5
Materials and services	-22.5	-26.3	0.4	-	-48.4
Employee benefits	-17.1	-18.3	0.1	-	-35.4
Depreciation, amortization and impairment	-3.0	-1.9	-2.1	-	-7.0
Other operating expenses	-19.7	-9.8	7.1	-	-22.4
Operating profit	4.8	-0.8	5.2	-	9.2
Share of profit of investments accounted for using the equity method	0.1	0.4	-	-	0.5
Financial income and expenses	0.6	-4.0	0.0	3.3	-0.1
Profit before taxes	5.5	-4.4	5.2	3.3	9.7
Income taxes	-2.5	-0.5	-1.0	0.2	-3.7
Profit for the period	3.0	-4.8	4.2	3.5	6.0
Other comprehensive income items	0.2	0.2	-	-	0.4
Total comprehensive income for the period	3.3	-4.7	4.2	3.5	6.4
Profit for the period attributable to:					
Owners of the parent	3.0	-4.8	4.2	3.5	6.0
Non-controlling interests	0.0	-	-	-	0.0
Total comprehensive income for the period attributable to:					
Owners of the parent	3.3	-4.7	4.2	3.5	6.4
Non-controlling interests	0.0	-	-	-	0.0

[1]Visionix financial information is adjusted for January-May, as Visionix has been included in Revenio's consolidated figures since the beginning of June 2026.

Unaudited Condensed Combined Pro Forma Income Statement

For the year ended December 31, 2025

MEUR	Revenio historical	Visionix reclassified (note 1)	Transaction (note 2)	Financing (note 3)	Revenio pro forma
Net sales	109.7	143.6	-0.5	-	252.8
Other operating income	0.2	0.1	-	-	0.3
Materials and services	-31.9	-66.7	-1.3	-	-99.8
Employee benefits	-26.4	-42.1	-0.1	-	-68.6
Depreciation, amortization and impairment	-4.5	-4.7	-4.9	-	-14.1
Other operating expenses	-21.7	-20.2	-7.1	-	-49.0
Operating profit	25.4	10.0	-13.8	-	21.6
Share of profit of investments accounted for using the equity method	-	0.1	-	-	0.1
Financial income and expenses	-2.6	-11.5	0.0	2.0	-12.1
Profit before taxes	22.8	-1.4	-13.8	2.0	9.5
Income taxes	-5.4	-2.8	2.1	1.0	-5.2
Profit for the period	17.4	-4.3	-11.7	2.9	4.3
Other comprehensive income items	-0.2	0.1	-	-	-0.1
Total comprehensive income for the period	17.2	-4.2	-11.7	2.9	4.2
Profit for the period attributable to:					
Owners of the parent	17.4	-4.3	-11.7	2.9	4.3
Non-controlling interests	-	-	-	-	-
Total comprehensive income for the period attributable to:					
Owners of the parent	17.2	-4.2	-11.7	2.9	4.2
Non-controlling interests	-	-	-	-	-

Pro forma key figures

MEUR, unless otherwise indicated	1-6/2026	1-12/2025
Net sales	121.9	252.8
Gross margin	73.4	152.9
Gross margin-%	60.3%	60.5%
EBITDA	16.2	35.7
EBITDA-%	13.3%	14.1%
Adjusted EBITDA	17.4	45.3
Adjusted EBITDA-%	14.3%	17.9%
EBITA	13.4	29.8
EBITA-%	11.0%	11.8%
Adjusted EBITA	14.6	39.3
Adjusted EBITA-%	12.0%	15.6%
Operating profit	9.2	21.6
Operating profit-%	7.6%	8.5%
Adjusted operating profit	10.5	31.1
Adjusted operating profit-%	8.6%	12.3%
Profit before taxes	9.7	9.5
Profit before taxes-%	7.9%	3.8%
Profit for the period	6.0	4.3
Profit for the period-%	4.9%	1.7%

Reconciliation of pro forma alternative performance measures

Pro forma adjusted EBITDA

MEUR	1-6/2026	1-12/2025
Operating profit, EBIT	9.2	21.6
Depreciation, amortization and impairment	7.0	14.1
EBITDA	16.2	35.7
Non-recurring items	1.3	9.6
Adjusted EBITDA	17.4	45.3

Pro forma adjusted EBITA

EUR million	1-6/2026	1-12/2025
Operating profit (IFRS)	9.2	21.6
Amortization	4.2	8.2
EBITA	13.4	29.8
Non-recurring items	1.3	9.6
Adjusted EBITA	14.6	39.3

Pro Forma Adjusted Operating Profit

MEUR	1-6/2026	1-12/2025
Operating profit, EBIT	9.2	21.6
Non-recurring items	1.3	9.6
Adjusted operating profit, EBIT	10.5	31.1

Notes to the unaudited pro forma financial information

Note 1 – Visionix reclassification

Visionix presents its income statement using a function-based format, whereas Revenio presents its con-solidated income statement using a nature-based format. Accordingly, Visionix's income statement line items have been reclassified from the function-based presentation (cost of sales, research and development expenses, sales and marketing expenses, general and administrative expenses and other expenses, net) to Revenio's nature-based presentation (materials and services, employee benefits, depreciation, amortisation and impairment, and other operating expenses).

Note 2 – Transaction adjustments

Elimination of intercompany transactions

Transactions between Revenio and Visionix have been eliminated in the pro forma financial information. These eliminations decreased net sales and materials and services by EUR 0.3 million for 1-6/2026 and by EUR 0.3 million for 1-12/2025. This adjustment will have a continuing impact on Revenio's results of operations.

Fair valuation adjustments

The pro forma adjustments reflect the fair valuation of net assets acquired in the Visionix Transaction. Amortisation from intangible assets recognised historically in Visionix's income statement, arising from previous purchase price allocations, has been eliminated. The identified intangible assets in the new purchase price allocation include customer relationships (amortised over 20 years), technology (amortised over 15 years) and brands (amortised over 20 years). Further, a fair value adjustment has been made to property, plant and equipment. In total, these adjustments increase the depreciation, amortisation and impairment in the pro forma financial information.

In addition, the income statement impact from fair value adjustment to deferred revenue of EUR 0.1 million for 1-6/2026 and EUR 0.1 million for the year 2025 have been recognised as a decrease in net sales, and the fair value adjustment to inventories of EUR 1.6 million has been recognised as additional expense in materials and services in the pro forma income statement for year 2025, of which EUR 0.1 million relating to June 2026 has been reversed in materials and services in the pro forma income statement for 1-6/2026. The related income tax impact has been calculated using the applicable blended tax rate of 13%.

Transaction costs

Total transaction costs incurred by Revenio and Visionix in connection with the Visionix Transaction amount to approximately EUR 7.3 million and primarily comprise financial, legal and advisory costs. For pro forma purposes, the total transaction costs have been presented in the pro forma income statement for the year 2025, of which EUR 7.1 million adjusted as other operating expenses and EUR 0.1 million as employee benefits. Transaction costs of EUR 7.1 million recognised as other operating expenses and EUR 0.1 million as employee benefits in Revenio's and Visionix' historical income statements for 1-6/2026 have been eliminated in the pro forma income statement for that period, in order to present all transaction costs in the pro forma income statement for the year 2025. The tax impact from the transaction costs related to Revenio has been calculated using the Finnish corporate income tax rate of 20%. No tax impact has been recognised for the transaction costs related to Visionix, as the relevant Visionix entities have been in a tax loss position.The transaction costs adjustment is not expected to have a continuing impact on Revenio's results of operations.

Note 3 – Financing Adjustments

The financing adjustments reflect the new loan arrangements entered into in connection with the Visionix Transaction, comprising a EUR 130 million amortising term loan facility, revolving credit facilities totaling EUR 20 million and EUR 17 million vendor loan arrangement as well as repayment of Revenio's and Visionix's previous loans. An interest rate swap with a notional amount of EUR 65 million has been entered into to hedge a portion of the floating rate exposure for the new term loan facility. The financing expenses related to Revenio's existing debt and Visionix's existing debt, which were repaid with the draw-down of new loans, have been eliminated and replaced with the financing expenses arising from the new arrangements. In total, the financing adjustments decrease the financial expenses in pro forma periods 1-6/2026 and 1-12/2025.

In the pro forma information, the bridge-to-equity facility of EUR 80 million is assumed to be already repaid with proceeds from the planned rights issue and no interest expense has therefore been recognised for that facility in the pro forma information. The interest expense recorded for the bridge-to-equity facility in Revenio's historical income statement for 1-6/2026 (EUR 0.2 million) has been eliminated.

The tax impact from the financing adjustments related to Revenio has been calculated using the Finnish corporate income tax rate of 20 %. No tax impact has been recognised for the financing adjustments related to Visionix, as the relevant Visionix entities have been in a tax loss position. The financing adjustments will have a continuing impact on Revenio's results of operations.

Financial reporting in 2026

The interim report Q3/2026 will be published on Thursday, November 12, 2026.

Audiocast and teleconference

Revenio will hold a live audiocast and teleconference call for analysts, investors, and media in English at 3.00 p.m. (EEST) on September 8, 2026. CEO Jouni Toijala and CFO Jukka Kainulainen will present the Half-year report.

The audiocast can be watched live at: **revenio.events.inderes.com/q2-2026**

To ask questions, please join the teleconference by registering using the following link:
events.inderes.com/revenio/q2-2026/dial-in

Phone numbers and the conference ID to access the conference will be provided after registration. To ask a question, please press #5 on your telephone keypad to enter the queue.

A recording of the audiocast will be published on **www.reveniogroup.fi/en** after the event.

Disclaimer

This report contains certain statements that are estimates based on the management's best knowledge at the time they were made. For this reason, they involve a certain amount of inherent risk and uncertainty. The estimates may change in the event of significant changes in the general economic conditions.

Revenio Group Corporation
Board of Directors

For further information, please contact

CEO Jouni Toijala: +358 50 484 0085

jouni.toijala@revenio.fi

CFO Jukka Kainulainen, tel. +358 40 533 6887

jukka.kainulainen@revenio.fi

Distribution

Nasdaq Helsinki Oy

Financial Supervisory Authority (FIN-FSA)

Principal media

www.reveniogroup.fi/en

Revenio Group in brief

Revenio is a leading turnkey solutions provider in the global eye care market. The group offers fast, user-friendly, and reliable tools for diagnosing a wide variety of eye diseases. Revenio's solutions include e.g. tonometers, fundus imaging devices, optical coherence tomography (OCT), perimeters, multimodal devices, refraction systems, and software solutions under iCare and Visionix.

In May 2026, Revenio joined forces with Visionix, creating the most innovative, creative and comprehensive entity serving eye care professionals across optometry, optical retail and ophthalmology. In 2025, the Group's net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.